Maravai LifeSciences Holdings Inc. Class A Common Stock vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while YieldMax Universe Fund of Option Income ETFs trades at $7.32 (market cap $365.95M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 2.7× YieldMax Universe Fund of Option Income ETFs's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and YieldMax Universe Fund of Option Income ETFs for 57 Days on average.
| MRVI | YMAX | |
|---|---|---|
Market Cap | $972.90M | $365.95M |
Volume | 4,325,710 | 1,000,945 |
Sector | Health | Income / Options Overlay |
52-Week High | $9.00 | $12.60 |
52-Week Low | $2.83 | $7.27 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $1.08B | — |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
YMAX trades at $7.61 with minimal daily movement (+0.13%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The fund maintains a high distribution policy with weekly dividends, but faces concerns about NAV erosion and sustainability. Recent portfolio adjustments aim to address performance issues while maintaining the ~40%+ annualized yield.
The outlook remains cautious due to structural concerns about distribution sustainability and NAV erosion. While the high yield attracts income investors, the fund's reverse split potential and stacked fee structure present significant risks. Analyst sentiment is mixed, with some questioning the long-term viability of the current distribution model amid persistent principal decline.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →